Literature DB >> 26434811

Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014).

J González-Macías1, J Del Pino-Montes2, J M Olmos1, X Nogués3.   

Abstract

These guidelines update issues covered in previous versions and introduce new ones that have arisen in recent years. The former refer mainly to the therapeutic developments that have been made during this time (zoledronate, denosumab, bazedoxifene), which have led to a change in the drug selection algorithm. The latter deal with therapeutic management, the description of new adverse effects (which have led to changes in therapeutic behaviour patterns, as is the case with atypical fracture of the femur), treatment duration (with consideration for the so-called "therapeutic holidays"), the so-called sequential treatment and changes in treatment imposed by certain circumstances. A new algorithm has been introduced for sequential treatment. Attention has also been paid to vertebroplasty and kyphoplasty.
Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Medicina Interna (SEMI). All rights reserved.

Entities:  

Keywords:  Clinical guidelines; Corticoides; Corticosteroids; Guías clínicas; Male; Osteoporosis; Posmenopausia; Postmenopause; Varón

Year:  2015        PMID: 26434811     DOI: 10.1016/j.rce.2015.08.003

Source DB:  PubMed          Journal:  Rev Clin Esp (Barc)        ISSN: 2254-8874


  11 in total

Review 1.  The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.

Authors:  Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2019-04-08       Impact factor: 3.633

Review 2.  Denosumab in the treatment of glucocorticoid-induced osteoporosis.

Authors:  Ilke Coskun Benlidayi
Journal:  Rheumatol Int       Date:  2018-07-17       Impact factor: 2.631

3.  Bone health in long-term gastric cancer survivors: A prospective study of high-dose vitamin D supplementation using an easy administration scheme.

Authors:  Marta Climent; Manuel Pera; Isabel Aymar; José M Ramón; Luis Grande; Xavier Nogués
Journal:  J Bone Miner Metab       Date:  2017-08-01       Impact factor: 2.626

Review 4.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

Review 5.  Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines.

Authors:  Roberto Coronado-Zarco; Andrea Olascoaga-Gómez de León; Araceli García-Lara; Jimena Quinzaños-Fresnedo; Tania Inés Nava-Bringas; Salvador Israel Macías-Hernández
Journal:  Osteoporos Sarcopenia       Date:  2019-10-04

6.  Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.

Authors:  José Luis Pérez-Castrillón; Antonio Dueñas-Laita; Maria Luisa Brandi; Esteban Jódar; Javier Del Pino-Montes; José Manuel Quesada-Gómez; Fernando Cereto Castro; Carlos Gómez-Alonso; Laura Gallego López; José Manuel Olmos Martínez; María Rosa Alhambra Expósito; Bernat Galarraga; Jesús González-Macías; Roger Bouillon; Gonzalo Hernández-Herrero; Nieves Fernández-Hernando; Paula Arranz-Gutiérrez; Sandra P Chinchilla
Journal:  J Bone Miner Res       Date:  2021-06-24       Impact factor: 6.390

Review 7.  Efficacy of Bracing on Thoracic Kyphotic Angle and Functionality in Women with Osteoporosis: A Systematic Review.

Authors:  Beatriz Sánchez-Pinto-Pinto; Carlos Romero-Morales; Daniel López-López; Carmen de-Labra; Guillermo García-Pérez-de-Sevilla
Journal:  Medicina (Kaunas)       Date:  2022-05-24       Impact factor: 2.948

8.  Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.

Authors:  Satoshi Soen; Miki Kaku; Naoki Okubo; Salsabil Touzeni; Kengo Saito; Makiko Kobayashi
Journal:  J Bone Miner Metab       Date:  2021-06-14       Impact factor: 2.626

9.  Update on Glucocorticoid Induced Osteoporosis.

Authors:  Soo-Kyung Cho; Yoon-Kyoung Sung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01

10.  Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom.

Authors:  M K Skjødt; S Khalid; M Ernst; K H Rubin; D Martinez-Laguna; A Delmestri; M K Javaid; C Cooper; C Libanati; E Toth; B Abrahamsen; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2020-03-17       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.